Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 341-346

  Aschele, C ^a   Guglielmi, A ^a   Frassineti, G L ^b   Milandri, C ^c   Amadori, D ^b   Labianca, R ^d   Vinci, M ^d   Tixi, L ^a   Caroti, C ^e   Ciferri, E ^a   Verdi, E ^a   Rosso, R ^a   Sobrero, A ^a,f  

^a UNIVERSITY OF GENOA   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Biochemical modulation; Natural interferon; Schedule of administration

Indexed keywords

BETA INTERFERON; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 14444267315     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.53     Document Type: Article

References (29)

1. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Advanced Colorectal Cancer Meta-Analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960-969
3. Aschele C, Sobrero A, Faderan MA and Bertino Jr (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864
4. Corfu - A Study Group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alpha 2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921-928
5. Frassineti GL, Giuliani R, Caroti C, Ravaioli A, Lanfranco C, Zonato S, Tosca N, Antonelli G, Labianca R, Caprioni F, Alghisi A, Arnoldi E, Barni S, Gallo L, Pessi MA, Guglielmi A, Turci D, Cortesi E, Milandri C, Aschele C and Sobrero A (1997) Sequential MTX→FU vs. schedule specific biochemical modulation in advanced colorectal cancer. Tumori 83: 40
6. Greco A, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A and Yap AKL (1996) Phase III randomised study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14: 2674-2681
7. Guglielmi A, Aschele C, Mori A, Baldo C, Russo P, Debernardis D, Valenti M, Bruno S, Taverna M, Rosso R and Sobrero A (1995) In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells. Clin Cancer Res 1: 1337-1344
8. Hansen R, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A III, Haller DG and Tormey DC (1996) Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88: 668-674
9. Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T, Nicolson M, O'Brien M, Iveson T, Iveson A and Evans C (1995a) Impact of protracted venous infusion fluorouracil with or without interferon alpha-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317-2323
10. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M and Hickish T (1995b) Royal Marsden phase III trial of fluorouracil with or without interferon alpha 2-B in advanced colorectal cancer. J Clin Oncol 13: 1297-1302
11. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944
12. Kaplan E and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-458
13. Kemeny N (1995) Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J Clin Oncol 13: 1287-1290
14. Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E and Fountzilas G for the Hellenic Cooperative Oncology Group (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 14: 2682-2687
15. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid Atlantic Oncology Program study. J Clin Oncol 7: 425-432
16. Mantel M (1963) Chi-square tests with one decree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58: 690-700
17. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
18. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA (1995) Fluorouracil plus levamisole after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326
19. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R and Sobrero A (1993) Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 33: 179-180
20. Seymour MT, Slevin M, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WAF, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP and Taylor I (1996) Randomized trial assessing the addition of interferon-alfa-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14: 2280-2288
21. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10: 1-10
22. Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Melioli GG, Rosso R and Bertino JR (1993) Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 85: 1937-1944
23. Sobrero A, Aschele C, Guglielmi A, Mori A, Tixi AM, Bolli EM, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, Bruzzi P and Bertino JR (1995) Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. Clin Cancer Res 1: 955-960
24. Sobrero A, Aschele C and Bertino JR (1997a) 5-Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation. J Clin Oncol 15: 368-381
25. Sobrero A, Labianca R, Frassineti GL, Ravaioli A, Lanfranco C, Zaniboni A, Arnoldi E, Barni S, Gallo L, Pessi MA, Guglielmi A, Turci D, Giuliani R, Milandri C, Caroti C, Grossi F, Aschele C and Bruzzi P (1997b) Randomized comparison between methotrexate → fluorouracil and schedule-specific biochemical modulation in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 16: 272
26. ser (IFNbeta) in patients with advanced colorectal carcinoma (abstract). Proc Am Soc Clin Oncol 14: 205
27. Weinerman B, Shah A, Fields A, Cripps IC, Wilson K, McCormick R, Temple W, Maroun J, Bogues W, Pater J and Zee B (1992) Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer, Am J Clin Oncol 15: 518-523
28. World Health Organization (1979) Handhook for Reporting Results of Cancer Treatment. WHO offset pubblication no. 48: Geneva, Switzerland
29. Wolmark N, Rockette H, Fisher B, Wickerham DL, Remond C, Fisher, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, Defusco PA and Jochimsem PJ (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Protocol-03. J Clin Oncol 11: 1879-1887